JP2005516004A - 新形成の治療 - Google Patents

新形成の治療 Download PDF

Info

Publication number
JP2005516004A
JP2005516004A JP2003550776A JP2003550776A JP2005516004A JP 2005516004 A JP2005516004 A JP 2005516004A JP 2003550776 A JP2003550776 A JP 2003550776A JP 2003550776 A JP2003550776 A JP 2003550776A JP 2005516004 A JP2005516004 A JP 2005516004A
Authority
JP
Japan
Prior art keywords
thc
apoptosis
cells
receptor
tumor cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003550776A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005516004A5 (https=
Inventor
ナガーカッティ，ミッツィ
ナガーカッティ，プラカシュ
マクカリップ，ロバート
ロムバード，キャセリン
リュー，ションギョ
Original Assignee
ヴァージニア コモンウェルス ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴァージニア コモンウェルス ユニバーシティ filed Critical ヴァージニア コモンウェルス ユニバーシティ
Publication of JP2005516004A publication Critical patent/JP2005516004A/ja
Publication of JP2005516004A5 publication Critical patent/JP2005516004A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2003550776A 2001-12-07 2002-12-09 新形成の治療 Pending JP2005516004A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33673201P 2001-12-07 2001-12-07
PCT/US2002/039310 WO2003049727A1 (en) 2001-12-07 2002-12-09 Treatment of neoplasia

Publications (2)

Publication Number Publication Date
JP2005516004A true JP2005516004A (ja) 2005-06-02
JP2005516004A5 JP2005516004A5 (https=) 2006-02-02

Family

ID=23317407

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003550776A Pending JP2005516004A (ja) 2001-12-07 2002-12-09 新形成の治療

Country Status (6)

Country Link
US (1) US20040259936A1 (https=)
EP (1) EP1461027A4 (https=)
JP (1) JP2005516004A (https=)
AU (1) AU2002357114B2 (https=)
CA (1) CA2468794A1 (https=)
WO (1) WO2003049727A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010509365A (ja) * 2006-11-13 2010-03-25 ノバルティス アーゲー Ｋｓｐ阻害剤としての置換ピラゾールおよびトリアゾール化合物

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7528165B2 (en) * 2001-12-13 2009-05-05 National Health Research Institutes Indole compounds
US7632955B2 (en) * 2001-12-13 2009-12-15 National Health Research Institutes Indole compounds
WO2005023232A2 (en) * 2003-09-04 2005-03-17 Affibody Ab Therapeutic, screening and diagnostic methods based on the effect of cb1 receptor modulation on lymphoproliferative disorders.
EP1736775A4 (en) * 2004-04-12 2008-03-12 Takeda Pharmaceutical NEW LIGAND OF A G-PROTEIN-COUPLED RECEPTOR PROTEIN AND USE THEREOF
TWI360539B (en) 2004-10-28 2012-03-21 Shionogi & Co 3-carbamoyl-2-pyridone derivatives
US7456289B2 (en) * 2004-12-31 2008-11-25 National Health Research Institutes Anti-tumor compounds
IN2012DN02474A (https=) 2009-08-28 2015-08-21 Arena Pharm Inc
KR20130020881A (ko) 2010-02-08 2013-03-04 알러간, 인코포레이티드 칸나비노이드-2 효능제로서 유용한 피리다진 유도체
AU2012222149B2 (en) 2011-02-25 2017-06-29 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
EP2678330A1 (en) 2011-02-25 2014-01-01 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of condensed azacycles ( cannabinoid receptor modulators)
US9597340B2 (en) 2011-02-25 2017-03-21 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
WO2016085941A1 (en) 2014-11-25 2016-06-02 Arena Pharmaceuticals, Inc. Processes for the preparation of cannabinoid receptor modulators
CA3140290A1 (en) * 2019-05-16 2020-11-19 Technion Research & Development Foundation Limited Cannabinoids and uses thereof
CN115282279B (zh) * 2022-08-08 2024-03-12 暨南大学附属第一医院（广州华侨医院） CNR2通过介导DCs成熟及功能作为脓毒症急性肺损伤治疗靶点的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1271266B (it) * 1994-12-14 1997-05-27 Valle Francesco Della Impiego terapeutico di ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi
FR2735774B1 (fr) * 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
ATE277921T1 (de) * 1998-05-04 2004-10-15 Univ Connecticut Selektiv auf den cb2-rezeptor wirkende cannabinoide
CA2387892A1 (en) * 1999-10-18 2001-04-26 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
FR2800372B1 (fr) * 1999-11-03 2001-12-07 Sanofi Synthelabo Derives tricycliques d'acide 1-benzylpyrazole-3- carboxylique, leur preparation, les medicaments en contenant
WO2001058869A2 (en) * 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010509365A (ja) * 2006-11-13 2010-03-25 ノバルティス アーゲー Ｋｓｐ阻害剤としての置換ピラゾールおよびトリアゾール化合物

Also Published As

Publication number Publication date
US20040259936A1 (en) 2004-12-23
EP1461027A1 (en) 2004-09-29
EP1461027A4 (en) 2005-09-07
WO2003049727A1 (en) 2003-06-19
AU2002357114B2 (en) 2008-07-24
AU2002357114A1 (en) 2003-06-23
CA2468794A1 (en) 2003-06-19

Similar Documents

Publication Publication Date Title
McKallip et al. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease
JP2005516004A (ja) 新形成の治療
Maestroni et al. Hematopoietic rescue via T-cell-dependent, endogenous granulocyte-macrophage colony-stimulating factor induced by the pineal neurohormone melatonin in tumor-bearing mice
EP1303265B1 (en) Use of cox-2 inhibitors as immunostimulants in the treatment of hiv or aids
EP2217231B1 (en) Use of 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives in leukemia management
Inoue et al. Resveratrol improves salivary dysfunction in a non-obese diabetic (NOD) mouse model of Sjögren’s syndrome
JP2015038107A (ja) ３，３’−ジインドリルメタン免疫活性化組成物
US11541030B2 (en) Methods for the treatment of inflammation associated with infection
CN103251585B (zh) 青蒿素及其衍生物在抑制血小板衍生生长因子受体a中的作用及其应用
ITMI971789A1 (it) Farmaco attivo nel ridurre la produzione di proteina mcp-1
Ben-Eliyahu et al. Timing within the oestrous cycle modulates adrenergic suppression of NK activity and resistance to metastasis: possible clinical implications
Liu et al. Effect of auranofin, an antirheumatic drug, on neutrophil apoptosis
Saito et al. Troglitazone, a selective ligand for PPARγ, induces cell-cycle arrest in human oral scc cells
AU2002252338B2 (en) Taurine compounds
AU2002252338A1 (en) Taurine compounds
Mahale et al. HDAC6 inhibition attenuates RIPK1/RIPK3/MLKL signalling and improves anti-tumor immune response in oral cancer
Helvaci et al. Smoking and sickle cell diseases
JPH11286455A (ja) 骨髄異形成症候群治療薬
Ogino et al. Indomethacin acts as an antitumor and anticachexic agent in colon 26-bearing CDF1 mice
EP1656147B1 (en) Diflunisal for the treatment of cancer
CN110063957A (zh) 厄洛替尼在制备flt3抑制剂类药物中的用途
Desai et al. Effects of Anesthesia on Cancer
Wang et al. Selective Inhibition of Natural Killer but not Natural Cytotoxic Activity in a Cloned Cell Line by Delta‐9‐Tetrahydrocannabinol
CN118845779A (zh) Ningetinib在治疗FLT3突变型白血病中的应用
CN116036126A (zh) 一种抗肿瘤的药物组合物及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090501

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090805

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091009